IgE plays a central role in the pathophysiology of allergic disorders. A humanized, monoclonal anti-IgE-antibody in the form of omalizumab is now available, which has a selective effect on the allergic disease process. This antibody binds exclusively to freely circulating IgE. Phase III studies in children and adults consistently showed that treatment with anti-IgE (omalizumab) led to significant reduction of asthma exacerbations and clinical complaints as well as intake of medication for asthma and allergic rhinitis. In another study approach for patients with a food allergy (peanuts), anti-IgE effected a higher tolerated allergic dose in oral provocation tests. The latter effect provides the possibility for preventive intervention in the allergic disease process with anti-IgE.
|Translated title of the contribution||Anti-IgE-antibody (omalizumab). Indication for treatment in pediatrics|
|Journal||Monatsschrift fur Kinderheilkunde|
|Number of pages||4|
|Publication status||Published - 07.2004|
Research Areas and Centers
- Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)